Ganymed Pharmaceuticals' IMAB362 to bring hope to gastric cancer patients, says analyst
New data regarding German biotech firm Ganymed Pharmaceuticals’ drug IMAB362, presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, provides hope for a subset of gastric and gastroesophageal junction adenocarcinoma (gastric cancer) patients with an advanced form of the disease, according to an analyst with research and consulting firm GlobalData.
As explored in GlobalData’s gastric cancer report, incidences of the disease are set to increase to over 410,000 by 2024 across the eight major markets of the USA, France, Germany, Italy, Spain, the UK, Japan, and China, which is indicative of the growing need for effective gastric cancer drugs, and the potential market open to IMAB362.
A randomized, open-label Phase II trial named FAST (NCT01630083) demonstrated that IMAB362, in combination with EOX (epirubicin, oxaliplatin and capecitabine) chemotherapy, significantly improved patients’ progression-free survival and overall survival of previously untreated, claudin18.2-positive advanced gastric cancer patients compared with EOX alone.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze